daratumumab + bortezomib + dexamethasone + dapagliflozin

This combination therapy, being investigated by Beijing Chao Yang Hospital, integrates the SGLT2 inhibitor dapagliflozin with the established D-Vd regimen (daratumumab, bortezomib, and dexamethasone) for the treatment of M-protein related cardiac disease, specifically cardiac amyloidosis. Daratumumab is a human IgG1k monoclonal antibody that targets CD38 on the surface of plasma cells, inducing cell death through multiple immune-mediated mechanisms. Bortezomib is a proteasome inhibitor that disrupts the degradation of intracellular proteins, leading to apoptosis in plasma cells. Dexamethasone is a potent glucocorticoid that provides synergistic anti-tumor activity and manages inflammation. Dapagliflozin is added to this backbone to provide cardioprotection and manage heart failure symptoms by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys, which promotes diuresis and reduces cardiac preload and afterload. This multi-targeted approach aims to both eliminate the underlying clone responsible for amyloid production and support cardiac function in patients with significant cardiac involvement.

Other names

Dapagliflozin + D-VdD-Vd + DapagliflozinDaratumumab + Bortezomib + Dexamethasone + Dapagliflozin